IntraBio
Elizabeth Weir Factor has an extensive work history. Starting in 1994, they worked as an Associate (Tax) at Cleary Gottlieb Steen & Hamilton LLP until 1996. From 1996 to 2004, they held the position of VP at Babcock & Brown. In 2002, they became a Member of the New York State Financial Control Board, a role they held until 2006. During this time, from 2004 to 2006, they also served as Director and Audit Committee Member at the United Nations Development Corporation. In 2005, they became a Commissioner at the New York State Commission on Public Authority Reform, a role they held until 2006. In 2016, they joined IntraBio Ltd. as a Director and later became the Chief Administrative Officer. Elizabeth Weir'smost recent role is as the Director at INSIGHT Philanthropy and Brand Consulting, starting in 2023.
Elizabeth Weir Factor has a Juris Doctor (JD) degree from Yale Law School. Elizabeth Weir also holds a Bachelor of Arts (BA) degree in American History from Columbia University. In addition, they attended The University of Edinburgh from 1989 to 1990, where they studied European History. Elizabeth Weir Factor's earlier education includes attending Phillips Academy and Ransom Everglades School, but no specific information regarding degrees or fields of study is available for these institutions.
This person is not in any teams
This person is not in any offices
IntraBio
IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases.Their clinical programs leverage the expertise of their scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developingsmall molecule drugs that modulate lysosomal function and intracellular calcium signaling.Their management team and business consultants have vast commercial and regulatory experience in drug product development, including all stages from small molecule manufacturing, clinical studies, and regulatory approvals in the USA and Europe.With their successful track record of drug development and commercialization, IntraBio’s team translates research in the fields of lysosomal biology, autophagy, and neurology into orphan drugs and treatments that will significantly improve the lives of patients, their caregivers, and families.